RWM
CORT icon

Rialto Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Rialto Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$174 – 1744
2025
Q4 		$174 Hold
5
– – ﹤0.01% 1550
2025
Q3 		$416 Buy
5
+2
+67% +$145 ﹤0.01% 1309
2025
Q2 		$221 Buy
+3
New +$218 ﹤0.01% 1351

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Rialto Wealth Management's CORT Position: Q1 2026 in Review

Rialto Wealth Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 5 shares — an estimated $174 sold.

Rialto Wealth Management first reported a position in CORT in Q2 2025 and held it in 3 quarters. The position peaked at $416 in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Rialto Wealth Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rialto Wealth Management sold 5 Corcept Therapeutics shares in Q1 2026, an estimated $174.
  • Rialto Wealth Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 3 quarters.
  • Rialto Wealth Management's Corcept Therapeutics position peaked at $416 in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.